Homology Medicines, Inc. announced that it achieved all corporate goals for 2018, positioning the Company to start a Phase 1/2 clinical trial of the Company’s first gene therapy program in adults with phenylketonuria (PKU), with initial data expected in 2019. Homology closed out the year by nominating development candidates for two additional programs focused on pediatric rare genetic diseases, both of which have entered into IND-enabling studies. These candidates comprise a nuclease-free in vivo gene editing approach for PKU and a gene therapy approach for metachromatic leukodystrophy (MLD), Homology’s lead central nervous system (CNS) program and a fatal pediatric lysosomal storage disorder. Pipeline advancements are expected to be supported by Homology’s newly completed GMP gene therapy and gene editing manufacturing facility.